tbuckley/cabot-search huggingface dataset:
Chronic Lymphocytic Leukemia: Evaluation of Cytogenetic Markers as Prognostic Factors
Authors: Jose Carda, Patricia Sousa, Patricia Olim, Emília Magalhães, Luis Rito, Rui Afonso, Braz Luz, Catarina Geraldes, Marilene Vivan, Emília Cortesão, Lénia Jorge, Isabel Sousa, Adriana Teixeira
Journal: Blood (2010)
Significance of ELN Provisional Response Definitions In Predicting Long-Term Outcomes of Patients with CP-CML Treated with Dasatinib After Imatinib Failure.
Authors: Jorge E. Cortes, Neil P. Shah, Charles A. Schiffer, Philipp D. LeCoutre, Giuseppe Saglio, Alfonso Quintás-Cardama, Hagop Kantarjian, Elias Jabbour, Erkut Bahceci, Allen Chen, Alexandre Lambert, Francois Guilhot
Journal: Blood (2010)
Rare and common epilepsies converge on a shared gene regulatory network providing opportunities for novel antiepileptic drug discovery
Authors: Andree Delahaye-Duriez, Prashant Srivastava, Kirill Shkura, Sarah R. Langley, Liisi Laaniste, Aida Moreno-Moral, Bénédicte Danis, Manuela Mazzuferi, Patrik Foerch, Elena V. Gazina, Kay Richards, Steven Petrou, Rafal M. Kaminski, Enrico Petretto, Michael R. Johnson
Journal: Genome biology (2016)

The relationship between monogenic and polygenic forms of epilepsy is poorly understood and the extent to which the genetic and acquired epilepsies share common pathways is unclear. Here, we use an integrated systems-level analysis of brain gene expression data to identify molecular networks disrupted in epilepsy. We identified a co-expression network of 320 genes (M30), which is significantly enriched for non-synonymous de novo mutations ascertained from patients with monogenic epilepsy and for common variants associated with polygenic epilepsy. The genes in the M30 network are expressed widely in the human brain under tight developmental control and encode physically interacting proteins involved in synaptic processes. The most highly connected proteins within the M30 network were preferentially disrupted by deleterious de novo mutations for monogenic epilepsy, in line with the centrality-lethality hypothesis. Analysis of M30 expression revealed consistent downregulation in the epileptic brain in heterogeneous forms of epilepsy including human temporal lobe epilepsy, a mouse model of acquired temporal lobe epilepsy, and a mouse model of monogenic Dravet (SCN1A) disease. These results suggest functional disruption of M30 via gene mutation or altered expression as a convergent mechanism regulating susceptibility to epilepsy broadly. Using the large collection of drug-induced gene expression data from Connectivity Map, several drugs were predicted to preferentially restore the downregulation of M30 in epilepsy toward health, most notably valproic acid, whose effect on M30 expression was replicated in neurons. Taken together, our results suggest targeting the expression of M30 as a potential new therapeutic strategy in epilepsy.
Early Molecular Response (EMR) with Frontline Treatment Is a Significant Predictor of Long-Term BCR-ABL Transcript Levels in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML) in Chronic Phase
Authors: Giuseppe Saglio, Sonya J. Snedecor, Xiang Ji, Ming-Hui Tai, David Ray, Estella Mendelson, Aby Buchbinder, Pascal Edrich, Francois-Xavier Mahon
Journal: Blood (2015)
MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia,
Authors: Christopher P. Rombaoa, Yong Zhang, Ranjit Banwait, Yang Liu, Hai T Ngo, Phong Quang, Abdel Kareem Azab, Feda Azab, Patricia Maiso, Michaela Reagan, Antonio Sacco, Aldo M Roccaro, Jennifer R. Brown, Irene M. Ghobrial
Journal: Blood (2011)
Monocytosis in the Peripheral Blood At First Relapse/Progression Predicts Poorer Overall and Progression-Free Survival After Autologous Hematopoietic Stem Cell Transplantation in Hodgkin Lymphoma
Authors: Marie Toft-Petersen, Peter Kamper, Signe Albertsen, Louise Secher, Erik Kay Segel, Michael Clausen, Francesco d'Amore
Journal: Blood (2011)
Identification of a Dynamic Core Transcriptional Network in t(8;21) AML Regulating Differentiation Block and Self-Renewal
Authors: Anetta Ptasinska, Salam Assi, Natalia Martinez-Soria, Maria Rosaria Imperato, Jason Piper, Pierre Cauchy, Anna Pickin, Sally James, Maarten Hoogenkamp, Daniel G Tenen, Sascha Ott, David R Westhead, Peter N Cockerill, Olaf Heidenreich, Constanze Bonifer
Journal: Blood (2014)
Dendrimer‐Stabilized Gold Nanostars as a Multifunctional Theranostic Nanoplatform for CT Imaging, Photothermal Therapy, and Gene Silencing of Tumors
Authors: Ping Wei, Jingwen Chen, Yong Hu, Xin Li, Han Wang, Mingwu Shen, Xiangyang Shi
Journal: Advanced Healthcare Materials (2016)

Development of versatile nanomaterials combining diagnostic and therapeutic functionalities within one single nanoplatform is extremely important for tumor theranostics. In this work, the authors report the synthesis of a gold nanostar (Au NS)-based theranostic platform stabilized with cyclic arginine-glycine-aspartic (Arg-Gly-Asp, RGD) peptide-modified amine-terminated generation 3 poly(amidoamine) dendrimers. The formed RGD-modified dendrimer-stabilized Au NSs (RGD-Au DSNSs) are used as a gene delivery vector to complex small interfering RNA (siRNA) for computed tomography (CT) imaging, thermal imaging, photothermal therapy (PTT), and gene therapy of tumors. The results show that the RGD-Au DSNSs are able to compact vascular endothelial growth factor siRNA and specifically deliver siRNA to cancer cells overexpressing αv β3 integrin. Under near-infrared laser irradiation, the viability of cancer cells is only 20.2% after incubation with the RGD-Au DSNS/siRNA polyplexes, which is much lower than that of cells after single PTT or gene therapy treatment. Furthermore, in vivo results show that the RGD-Au DSNS/siRNA polyplexes enable tumor CT imaging, thermal imaging, PTT, and gene therapy after intratumoral injection. These results indicate that the developed multifunctional nanoconstruct is a promising platform for tumor imaging and combinational PTT and gene therapy.
Bortezomib Combined with VXLD Chemotherapy Is Highly Effective In Advanced B-Lineage Acute Lymphoblastic Leukemia Allowing Early Study Termination Due to Efficacy. A Therapeutic Advances in Childhood Leukemia (TACL) Consortium Phase II Study
Authors: Yoav H Messinger, Paul Gaynon, Richard Sposto, Jeannette van der Giessen, Elena Eckroth, Jemily Malvar, Bruce C. Bostrom
Journal: Blood (2011)
Impact of Donor IL-7Rα Polymorphism On Recipient Plasma IL-7 levels and Acute Gvhd Following Allogeneic Stem Cell Transplantation.
Authors: Stephanie Thiant, Zaiba Shamim, Lars Peter, Valérie Coiteux, Jean Paul Dessaint, Myriam Labalette, Klaus Muller, Ibrahim Yakoub-Agha
Journal: Blood (2010)
A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD
Authors: Gérard Socié, Stéphane Vigouroux, Ibrahim Yakoub-Agha, Jacques-Olivier Bay, Sabine Fürst, Karin Bilger, Felipe Suarez, Mauricette Michallet, Dominique Bron, Philippe Gard, Zakaria Medeghri, Philippe Lehert, Chinglin Lai, Tim Corn, Jean-Paul Vernant
Journal: Blood (2016)
Adapting to Artificial Intelligence
Authors: Saurabh Jha, Eric J. Topol
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model
Authors: Willy A Noort, Richard W.J. Groen, Reinier Raymakers, Linda Aalders, Frans M Hofhuis, Berris Van Kessel, Jeroen F Van Velzen, Joost de Bruijn, Huipin Yuan, Jeroen Lammerts van Bueren, Andries C Bloem, Paul W.H.I. Parren, Henk Lokhorst, Tuna Mutis, Anton C.M. Martens
Journal: Blood (2012)
Results of a Prospective Non-Randomized Trial Comparing the Efficacy of Voriconazole (Vor) and Posaconazole (Pos) As Primary Prophylactic Agents of Invasive Fungal Infections (IFI) in Acute Leukemic Patients
Authors: Mario Ojeda-Uribe, Celine Haby, Alain Gravet, Catherine Berg, Olivier Aujoulat, Eric Jeandidier, Caroline Lohmann, Bernard Drenou, Benoît Lesquerbault
Journal: Blood (2011)
Detection of Common Chimeric Fusion Transcripts in Acute Lymphoblastic Leukemia (ALL) Patients Using Multiplex Reverse Transcriptase Polymerase Chain Reaction Assay: A North Indian Tertiary Care Centre Experience
Authors: Neelam Varma, Prateek Bhatia, Jogeshwar Binota, Ram Kumar Marwaha, Subhash Varma, Pankaj Malhotra
Journal: Blood (2011)
Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.
Authors: Asher Alban Chanan-Khan, Zhinuan Yu, Donna Weber, Christine Chen, Ruben Niesvizky, Andrew Spencer, Michel Attal, Andrew Belch, Miles Prince, Marta Olesnyckyj, Robert Knight, Jerome Zeldis, Meletius Dimopoulos
Journal: Blood (2006)
Minimal Residual Disease (MRD) Monitoring in CBFB-MYH11 Acute Myeloid Leukemia (AML) Is of Prognostic Relevance for Relapse-Free Survival.
Authors: Andrea Corbacioglu, Claudia Scholl, Karina Eiwen, Lars Bullinger, Stefan Frohling, Hartmut Dohner, Richard F. Schlenk, Konstanze Dohner
Journal: Blood (2006)
Status of the Immunoglobulin Heavy Chain and Light Chain Genes in Chronic Lymphocytic Leukemia and Related Disorders
Authors: Hirotaka Nakahashi, Masamitsu Karasawa, Akio Saito, Kohtaro Toyama, Takeki Mitsui, Yoko Hashimoto, Hiromi Koiso, Akihiko Yokohama, Hideki Uchiumi, Takayuki Saitoh, Hiroshi Handa, Norifumi Tsukamoto, Hirokazu Murakami, Yoshihisa Nojima
Journal: Blood (2008)
Treatment of Severe Aplastic Anaemia (SAA) with Antilymphocyte Globulin (ALG), Cyclosporine (CyA) and Granulocyte Colony Stimulating Factor (G-CSF) 5 μG vs 10 μG/Kg : A Gitmo Prospective Randomized Study.
Authors: Anna Locasciulli, Barbara Bruno, Alessandro Rambaldi, Paola Saracco, Carlo Dufour, Carlo Finelli, Simona Sica, Stefania Varotto, William Arcese, Franco Locatelli, Davide Soligo, Andrea Bacigalupo
Journal: Blood (2004)
ACTR-20. INITIAL RESULTS OF PLX108-08: AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PEXIDARTINIB (PLX3397) IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Howard Colman, Jeffrey Raizer, Tobias Walbert, Scott Plotkin, Marc Chamberlain, Eric Wong, Vinay Puduvalli, David Reardon, Fabio Iwamoto, Brett Johnson, Karthik Sonty, Bill Welbourn, David Karlin, Michael Pelayo, Marguerite Hutchinson, Henry Hsu
Journal: Neuro-Oncology (2016)

Pexidartinib (PEX) is a small molecule inhibitor of KIT and the CSF1 receptor expressed on microglia, blood vessels, and glioblastoma (GBM) tumor cells. A prior recurrent GBM study showed that PEX readily crossed the blood-brain barrier. Preclinical studies indicate that PEX effects on tumor and microenvironment may sensitize newly diagnosed GBM to standard therapy. Phase Ib dose escalation determined the recommended Phase II dose (RP2D) with XRT and TMZ. Phase II primary endpoint was progression free survival (PFS); secondary endpoints included overall survival (OS) and safety. Patient inclusion/exclusion were designed to replicate the RTOG 0525 control arm, which was used as historical control. PEX 400mg BID daily 5 days/week during and 7 days/week after XRT was identified as the RP2D. In Phase II, 42 of 44 patients were evaluable. Prognostic factors showed good concordance between PEX population and the RTOG 0525 control arm. 28 of 42 patients experienced a PFS event. Median PFS from registration is 9.7 months in PEX patients (95% CI 7.3, 13.2) vs. 7.5 months in historical controls (p= 0.035)(HR 0.71, (95% CI 0.49, 1.03)). Initial OS analyses show 8 of 42 PEX patients with events at 9-months vs. 13.1 expected deaths in controls (p=0.046) and 12-month OS events of 9 (PEX) vs. 16.8 (expected control) (p=0.029). Estimated mOS for PEX is 25.1 months (95% CI 15.7, 41.0) vs. 18.9 months controls (p=0.108)(HR 0.72, 95% CI 0.43, 1.21), and updated data will be presented as additional events occur. PEX was well tolerated, with most common drug-related toxicities including neutropenia and increased ALT/AST. PEX 400mg BID can be safely combined with XRT/TMZ in newly diagnosed GBM. Initial Phase II results suggest promising effects of PEX in improving PFS and OS compared to robust, well-matched historical controls. Further investigation of PEX in randomized trials is warranted.
Relapsed Acute Myeloid Leukemia in Children and Adolescents: Interim Results of the International Randomised Phase III Study “Relapsed AML 2001/01”.
Authors: Gertjan J. Kaspers, M. Zimmermann, G. Fleischhack, R. Tamminga, B. Gibson, H. Armendariz, M. Dworzak, S. Ha, L. Hovi, A. Maschan, N. Philippe, B. Razzouk, C. Rizzari, P. Smisek, O. Smith, B. Stark, U. Creutzig
Journal: Blood (2005)
Proteomic Profiling of 112 Proteins in Chronic Myeloid Leukemia Patient Samples Using Reverse Phase Proteins Arrays (RPPA) Reveals Distinct Protein Expression Signatures Associated with Advanced Phase Disease and the CD34+ Compartment
Authors: Alfonso Quintás-Cardama, Yi Hua Qiu, Sean Post, Yiqun Zhang, Chad Creighton, Jorge E. Cortes, Steven M. Kornblau
Journal: Blood (2011)
Thrombophilic Factors in Retinal Vessel Thrombosis: A Single Center Experience
Authors: Nicole Maxey, Zeinab Mohammadi, Pamela Dominguez-Perez, Erasto Cortes, Nishaal Antony, Mark M Landeros, Carmen Arango, Angel Campos-Gines, Carlos W Vazquez, Juan Herrada
Journal: Blood (2015)
MALDI-TOF/MS identification of species from the Acinetobacter baumannii (Ab) group revisited: inclusion of the novel A. seifertii and A. dijkshoorniae species
Authors: M. Marí-Almirall, C. Cosgaya, P.G. Higgins, A. Van Assche, M. Telli, G. Huys, B. Lievens, H. Seifert, L. Dijkshoorn, I. Roca, Jordi Vila
Journal: Clinical Microbiology and Infection (2016)
Allogeneic Transplantation with CCR5 Δ32/Δ32 Cord Blood Hematopoietic Cells in a HIV-Infected Patient
Authors: Rafael F. Duarte, María Salgado, Isabel Sánchez-Ortega, Montserrat Arnan, Carmen Canals, Eva Domingo, Alberto Fernández de Sevilla, Xavier García-Pont, Eva González-Barca, Sara Morón-López, Nuria Nogues, Beatriz Patiño, Maria Carmen Puertas, Bonaventura Clotet, Lawrence D. Petz, Sergio Querol, Javier Martinez-Picado
Journal: Blood (2014)
Travel-Associated Zika Virus Disease Acquired in the Americas Through February 2016
Authors: Davidson H. Hamer, Kira A. Barbre, Lin H. Chen, Martin P. Grobusch, Patricia Schlagenhauf, Abraham Goorhuis, Perry J.J. van Genderen, Israel Molina, Hilmir Asgeirsson, Phyllis E. Kozarsky, Eric Caumes, Stefan H. Hagmann, Frank P. Mockenhaupt, Gilles Eperon, Elizabeth D. Barnett, Emmanuel Bottieau, Andrea K. Boggild, Philippe Gautret, Noreen A. Hynes, Susan Kuhn, R. Ryan Lash, Karin Leder, Michael Libman, Denis J.M. Malvy, Cecilia Perret, Camilla Rothe, Eli Schwartz, Annelies Wilder-Smith, Martin S. Cetron, Douglas H. Esposito
Journal: Annals of Internal Medicine (2016)

Background: Zika virus has spread rapidly in the Americas and has been imported into many nonendemic countries by travelers. Objective: To describe clinical manifestations and epidemiology of Zika virus disease in travelers exposed in the Americas. Design: Descriptive, using GeoSentinel records. Setting: 63 travel and tropical medicine clinics in 30 countries. Patients: Ill returned travelers with a confirmed, probable, or clinically suspected diagnosis of Zika virus disease seen between January 2013 and 29 February 2016. Measurements: Frequencies of demographic, trip, and clinical characteristics and complications. Results: Starting in May 2015, 93 cases of Zika virus disease were reported. Common symptoms included exanthema (88%), fever (76%), and arthralgia (72%). Fifty-nine percent of patients were exposed in South America; 71% were diagnosed in Europe. Case status was established most commonly by polymerase chain reaction (PCR) testing of blood and less often by PCR testing of other body fluids or serology and plaque-reduction neutralization testing. Two patients developed Guillain–Barré syndrome, and 3 of 4 pregnancies had adverse outcomes (microcephaly, major fetal neurologic abnormalities, and intrauterine fetal death). Limitation: Surveillance data collected by specialized clinics may not be representative of all ill returned travelers, and denominator data are unavailable. Conclusion: These surveillance data help characterize the clinical manifestations and adverse outcomes of Zika virus disease among travelers infected in the Americas and show a need for global standardization of diagnostic testing. The serious fetal complications observed in this study highlight the importance of travel advisories and prevention measures for pregnant women and their partners. Travelers are sentinels for global Zika virus circulation and may facilitate further transmission. Primary Funding Source: Centers for Disease Control and Prevention, International Society of Travel Medicine, and Public Health Agency of Canada.
NK4, an Antagonist of Hepatocyte Growth Factor (HGF), Inhibits Growth of Multiple Myeloma Cells In Vitro and In Vivo: A Mouse Model for Molecular Targeting of Angiogenic Growth Factor.
Authors: Yutaka Hattori, Wenlin Du, Taketo Yamada, Kunio Matsumoto, Toshikazu Nakamura, Takemi Otsuki, Takako Niikura, Toshihiro Nukiwa, Yasuo Ikeda
Journal: Blood (2004)
Cytomegalovirus (CMV) Infection after Umbilical Cord Blood Transplantation and Evaluation of Donor Screening Strategies.
Authors: Maria S. Albano, Patricia E. Taylor, Robert F. Pass, Andromachi Scaradavou, Rodica Ciubotariu, Carmelita Carrier, Ludy Dobrila, Pablo Rubinstein, Cladd E. Stevens
Journal: Blood (2006)
Importance of DNMT3A Gene mutations detection in Prognostic Analyses of Patients with Acute Myeloid Leukemia
Authors: Ekaterina Petrova, Irina Martynkevich, Lyubov Polushkina, Lyudmila Martynenko, Marina Ivanova, Natalya Cybakova, Elena Shabanova, Ilya Zyuzgin, Elena Karyagina, Sergey Gritsaev, Kudrat Abdulkadyrov
Journal: Blood (2014)
The Novel CXCR4 Antagonist POL5551 Decreases Surface CXCR4 (s-CXCR4) Expression, Inhibits Chemotaxis, and Enhances Chemosensitivity in Acute Lymphoblastic Leukemia (ALL)
Authors: Edward Allan R. Sison, Daniel Magoon, Eric Chevalier, Klaus Dembowsky, Patrick Brown
Journal: Blood (2012)
Psychological readiness to return to sport: three key elements to help the practitioner decide whether the athlete is REALLY ready?
Authors: Dale Forsdyke, Adam Gledhill, Clare Ardern
Journal: British Journal of Sports Medicine (2016)

Return to sport (RTS) outcomes after severe injury are consistently poor.1 ,2 Psychological factors are important influences on returning to sport3 yet what it means to be psychologically ready to RTS is unclear.4 Rarely will an athlete be held back from RTS because he/she is not psychologically ready to return. Psychological factors correlate with injury occurrence,5 therefore these factors should be offered greater weighting in RTS decision-making.

Characteristics of an athlete who is psychologically ready to RTS are multifaceted and include, among others: realistic expectations, high levels of self-efficacy and low levels of anxiety.1 ,4 ,6 Psychological readiness to RTS is likely influenced by multiple social agents, personal and contextual factors (eg, coaches, sports medicine practitioners, personality traits, performance level).4 Consequently, RTS decisions should be made from an interdisciplinary perspective, with multidimensional monitoring of psychological factors (eg, concurrently monitoring self-efficacy and re-injury anxiety levels).6

Psychological readiness to RTS is not commonly monitored in practice, despite specific instruments being available.7 Many practitioners feel underprepared to work within this area8 or might view evaluating psychological readiness to RTS as being outside their scope of their practice. On the …
SNP Array Analysis in Refractory Anemia with Ringed Sideroblast Allows for Detection of a High Frequency of Previously Cryptic Chromosomal Defects with Possible Clinical Significance.
Authors: Abdo S. Haddad, Lukasz P. Gondek, Araf Alkali, Mikkael A. Sekeres, Alan Lichtin, Go Yamamoto, Seishi Ogawa, Jaroslaw P. Maciejewski
Journal: Blood (2006)
Expansion of Immature/Transitional B-Lymphocytes in Patients with Active Chronic Graft-Versus-Host Disease.
Authors: Michal Kouba, Hildegard T. Greinix, David Pohlreich, Ulrike Körmöczi, Imke Lohman, Peter Kalhs, Christoph Zielinski, Winfried Pickl
Journal: Blood (2007)
Early Fludarabine Treatment of TCL-1 Transgenic Mice Promotes Drug Resistance through a Mechanism Not Involving p53 Mutations: Implications for Patients with Chronic Lymphocytic Leukemia (CLL).
Authors: Michael D. De Lay, Amy J. Johnson, David M. Lucas, Darius T. Durr, Ellen M. Sass, Virginia M. Goettl, Amy Lehman, David Jarjoura, Michael R. Grever, John C. Byrd
Journal: Blood (2007)
Occupational Diseases: Diagnosis, Medicolegal Aspects and Treatment
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Primary Central Nervous System Lymphoma of T Cell Origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group.
Authors: Tamara Shenkier, Jean-Yves Blay, Brian P. O’Neill, Philip Poortmans, Kristoph Janke, Lauren E. Abrey, Edward Neuwelt, Richard Tsang, Tracy Batchelor, Nancy Harris, Andres J. Ferreri, Maurilio Ponzoni, Peter O’Brien, James Rubenstein, Joseph M. Connors
Journal: Blood (2004)
Activation of HIV-1-Specific CD8+ and CD4+ Autologous Memory T-Cells by Dendritic Cells and B-Cells Electroporated with mRNA Encoding Consensus or Autologous HIV-1 Proteins.
Authors: Zwi N. Berneman, Ellen R.A. Van Gulck, Glenn Van den Bosch, Peter Ponsaerts, Leo Heyndrickx, Filip Moerman, Ann De Roo, Marc Lenjou, Griet Nijs, Dirk R. Van Bockstaele, Viggo F.I. Van Tendeloo, Concepcion Maranon, Anne Hosmalin, Guido Vanham
Journal: Blood (2005)